TrialStat eClinical Suite - Powering Virtual Clinical Trials
TrialStat® delivers data solutions on-demand for pharmaceutical, biotechnology, medical device companies, Contract Research Organizations and Data Management companies. Our TrialStat eClinical Suite™ consists of three fully unified product offerings - EDC, Portal and CTMS. We stand alone in the industry with such an all-compassing suite of products for conducting clinical trials.
EDC + eConsent + ePRO + Randomization + Coding
Powerful Data Capture, Real-Time Reporting and Trial Management Functionality In a Single Unified Suite.
TrialStat EDC
TrialStat EDC is a scalable, hosted, Electronic Data Capture Suite for pilot / proof of concept studies, Phase I, II, III and IV studies. In addition, TrialStat EDC is an ideal choice for the unique requirements of Medical Device and Diagnostic studies. TrialStat EDC uses the latest technology, allowing all users complete system access via any web browser or mobile device.
Explore TrialStat EDC
Visit the TrialStat EDC page to explore additional information and download the TrialStat EDC Overview.
TrialStat eConsent
Accelerate trial enrolment and maximize protocol compliance by leveraging TrialStat's comprehensive and immersive eConsent experience. Configurable workflows, support for witnesses, assent, re-consent, and the ability for patients to revoke consent.
TrialStat's eConsent is fully integrated with TrialStat's EDC or it can be used with other EDC platforms!
Explore TrialStat eConsent
Contact us today to find out more about the eConsent module and see how it works!
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?
Explore TrialStat's comprehensive eClinical Suite
Hover your mouse over each numbered item for a brief description
See TrialStat In Action
Request Your Personalized Demo. Our Clinical Team will organize a tailored demonstration of TrialStat based on your specific study requirements. You'll see first hand how TrialStats unified features, blazing speed, configurable features and comprehensive functionality will help you run more efficient and cost effective studies.
Premium Modules & Custom Development Services
A Fully Unified eClinical Suite Offering EDC functionality with Randomization (IWRS), Inventory Management, Medical Coding and ePRO in a single platform.
Custom Development
TrialStat is unique in the industry, providing validated custom development services. As a matter of practice, we regularly include new features based on Sponsor requirements. Our expert Software Architects, Software Developers and Compliance Experts provide complete custom development services to meet your unique requirements while ensuring compliance with all relevant regulatory requirements such as 21 CFR Part 11, HIPAA and Privacy Shield.
Tired of Hearing "No" All The Time?
Do you have requirements for your studies which other EDC platforms can't support?
Don't worry, at TrialStat we've developed our technology specifically for you. Our Expert Clinical Consultants and Software Developers will work with you to implement the features you need within our Validated eClinical Suite.
We're Hiring! Check Out Our Careers Page For Open Positions:
A Unified eClinical Suite Delivering Real-Time Data
See TrialStat In Action
Request Your Personalized Demo. Our Clinical Team will organize a tailored demonstration of TrialStat based on your specific study requirements. You'll see first hand how TrialStats unified features, blazing speed, configurable features and comprehensive functionality will help you run more efficient and cost effective studies.
Regulatory Compliance
TrialStat's entire Unified eClinical Suite is developed and deployed with an Agile Methodology and specifically engineered to comply with FDA 21 CFR Part 11 requirements for Electronic Records and Electronic Signatures, HIPAA, GDPR and FISMA. TrialStat maintains a Master Validation Plan and Change Control procedures.
Recent News, Updates & Announcements
Things are happening! Check back often or subscribe to our RSS Feed.
Cellevolve Bio Submits Investigational New Drug (IND) Application for Global Phase 2, Placebo-controlled Study of CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)
CE-VST-01-JC is a novel, allogeneic, off-the-shelf, T cell therapy that targets the JC Virus, the virus that causes progressive multifocal leukoencephalopathy (PML)ASCEND-JC is a randomized, double-blind, placebo-controlled, phase 2 study with sites planned across US, Europe, and CanadaLicensed and developed in collaboration with QIMR Berghofer Medical Research Institute’s Professor Rajiv Khanna; NIH’s Irene Cortese, M.D.…
Read More
Meet with Christopher Kata during the “24th Annual SoCalBio Conference” October 6th to 7th!
Christopher Kata is once again attending this years 24th Annual SocalBio Conference October 6th to 7th at the The West Long Beach. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or search him out at the meeting! Christopher Kata, Director of Sales & Marketing905 [email protected] When:…
Read More
Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
The SB101 and SB102 studies have together dosed 19 subjects to date This early review of safety sets the stage for further dose escalation Additional safety and cytokine-specific data are expected during the fourth calendar quarter of 2022 Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / September 21, 2022 / Sonnet BioTherapeutics Holdings,…
Read More